Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Novel drugs and intervention strategies for the treatment of chronic kidney disease.

Lambers Heerspink HJ, de Zeeuw D.

Br J Clin Pharmacol. 2013 Oct;76(4):536-50. doi: 10.1111/bcp.12195. Review.

2.

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.

Sharma P, Blackburn RC, Parke CL, McCullough K, Marks A, Black C.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007751. doi: 10.1002/14651858.CD007751.pub2. Review.

PMID:
21975774
3.

Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.

Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, Zhao N, Liu L, Lv J, Zhang H, Wang H.

Am J Kidney Dis. 2016 May;67(5):728-41. doi: 10.1053/j.ajkd.2015.10.011. Epub 2015 Nov 18.

PMID:
26597926
4.

Treatment of hypertension in chronic kidney disease.

Toto RD.

Semin Nephrol. 2005 Nov;25(6):435-9. Review.

PMID:
16298269
5.
6.

Aldosterone antagonists for preventing the progression of chronic kidney disease.

Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF.

Cochrane Database Syst Rev. 2014 Apr 29;(4):CD007004. doi: 10.1002/14651858.CD007004.pub3. Review.

PMID:
24782282
7.

Antioxidants for chronic kidney disease.

Jun M.

Nephrology (Carlton). 2013 Aug;18(8):576-8. doi: 10.1111/nep.12103. Review. No abstract available.

PMID:
23865542
8.

Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.

Mavrakanas TA, Gariani K, Martin PY.

Eur J Intern Med. 2014 Feb;25(2):173-6. doi: 10.1016/j.ejim.2013.11.007. Epub 2013 Dec 4. Review.

PMID:
24315413
9.

Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.

Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF.

Clin J Am Soc Nephrol. 2009 Mar;4(3):542-51. doi: 10.2215/CJN.04750908. Epub 2009 Mar 4. Review.

11.

2012 update on diabetic kidney disease: the expanding spectrum, novel pathogenic insights and recent clinical trials.

Fernández Fernández B, Elewa U, Sánchez-Niño MD, Rojas-Rivera JE, Martin-Cleary C, Egido J, Ortiz A.

Minerva Med. 2012 Aug;103(4):219-34. Review.

PMID:
22805616
12.

Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway.

Heerspink HJ.

Adv Chronic Kidney Dis. 2011 Jul;18(4):290-9. doi: 10.1053/j.ackd.2011.04.001. Review.

PMID:
21782135
13.

Emerging drugs for chronic kidney disease.

Stefoni S, Cianciolo G, Baraldi O, Iorio M, Angelini ML.

Expert Opin Emerg Drugs. 2014 Jun;19(2):183-99. doi: 10.1517/14728214.2014.900044. Epub 2014 May 16. Review.

PMID:
24836744
14.

Cardiovascular disease and its relationship with chronic kidney disease.

Liu M, Li XC, Lu L, Cao Y, Sun RR, Chen S, Zhang PY.

Eur Rev Med Pharmacol Sci. 2014 Oct;18(19):2918-26. Review.

15.

Dual renin-angiotensin system blockade for nephroprotection: still under scrutiny.

Gentile G, Remuzzi G, Ruggenenti P.

Nephron. 2015;129(1):39-41. doi: 10.1159/000368331. Epub 2014 Dec 16. Review.

16.

Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.

Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, Rossing P, Tarnow L.

Semin Nephrol. 2004 Mar;24(2):147-57. Review.

PMID:
15017527
17.

Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).

Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S, Warren SR, Peduzzi P; VA NEPHRON-D Investigators.

Clin J Am Soc Nephrol. 2009 Feb;4(2):361-8. doi: 10.2215/CJN.03350708. Epub 2008 Dec 31.

18.

Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.

Black C, Sharma P, Scotland G, McCullough K, McGurn D, Robertson L, Fluck N, MacLeod A, McNamee P, Prescott G, Smith C.

Health Technol Assess. 2010 Apr;14(21):1-184. doi: 10.3310/hta14210. Review.

19.

[Risk and prevention of diabetic nephropathy].

Ravera M, Re M, Deferrari G.

G Ital Nefrol. 2007 Sep-Oct;24 Suppl 38:13-9. Italian.

PMID:
17922442
20.

Multifactorial intervention with nurse practitioners does not change cardiovascular outcomes in patients with chronic kidney disease.

van Zuilen AD, Bots ML, Dulger A, van der Tweel I, van Buren M, Ten Dam MA, Kaasjager KA, Ligtenberg G, Sijpkens YW, Sluiter HE, van de Ven PJ, Vervoort G, Vleming LJ, Blankestijn PJ, Wetzels JF.

Kidney Int. 2012 Sep;82(6):710-7. doi: 10.1038/ki.2012.137. Epub 2012 Jun 27.

Supplemental Content

Support Center